Ellagic acid inhibits human colon cancer HCT-116 cells by regulating long noncoding RNAs

The natural phenolic compound ellagic acid exerts anti-cancer effects, including activity against colorectal cancer (CRC). Previously, we reported that ellagic acid can inhibit the proliferation of CRC, and can induce cell cycle arrest and apoptosis. This study investigated ellagic acid-mediated ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jinlu, Li, Guodong, Ren, Yi, Zhang, Zhicheng, Chen, Hongsheng, Zhang, Haopeng, Zhao, Xingyu, Li, Wang, Jia, Yucheng, Guan, Xue, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Pre-Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569677/
https://www.ncbi.nlm.nih.gov/pubmed/36847079
http://dx.doi.org/10.1097/CAD.0000000000001513
Descripción
Sumario:The natural phenolic compound ellagic acid exerts anti-cancer effects, including activity against colorectal cancer (CRC). Previously, we reported that ellagic acid can inhibit the proliferation of CRC, and can induce cell cycle arrest and apoptosis. This study investigated ellagic acid-mediated anticancer effects using the human colon cancer HCT-116 cell line. After 72 h of ellagic acid treatment, a total of 206 long noncoding RNAs (lncRNAs) with differential expression greater than 1.5-fold were identified (115 down-regulated and 91 up-regulated). Furthermore, the co-expression network analysis of differentially expressed lncRNA and mRNA showed that differential expressed lncRNA might be the target of ellagic acid activity in inhibiting CRC.

Ejemplares similares